Back to Search
Start Over
Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
- Source :
- Vaccine. 40(47)
- Publication Year :
- 2022
-
Abstract
- BPZE1 is a live, attenuated pertussis vaccine derived from B. pertussis strain Tohama I modified by genetic removal or inactivation of 3 B. pertussis toxins: pertussis toxin, dermonecrotic toxin, and tracheal cytotoxin. This Phase 2a study evaluated the safety and immunogenicity of liquid or lyophilized BPZE1 vaccine administered intranasally by needleless tuberculin syringe or mucosal atomization device (VaxINatorFifty healthy male and non-pregnant female participants 18-49 years of age were enrolled. Participants were randomized 3:3:3:1 to a single lyophilized dose of 10Across all groups, 35/50 (70 %) experienced at least one local adverse event (AE) and 31/50 (62 %) experienced at least one systemic AE, with similar AE frequencies observed between the highest 10Lyophilized BPZE1 vaccine was well tolerated and immunogenic at the highest dose (10
- Subjects :
- Adult
Male
Pertussis Vaccine
General Veterinary
General Immunology and Microbiology
Whooping Cough
Public Health, Environmental and Occupational Health
Tuberculin
Vaccines, Attenuated
Bordetella pertussis
Infectious Diseases
Immunogenicity, Vaccine
Molecular Medicine
Humans
Female
Administration, Intranasal
Subjects
Details
- ISSN :
- 18732518
- Volume :
- 40
- Issue :
- 47
- Database :
- OpenAIRE
- Journal :
- Vaccine
- Accession number :
- edsair.doi.dedup.....363bb7e8fedd10c251e2c2c1821770fd